DEVELOPING A PORTABLE VEST CPR APPARATUS

开发便携式背心心肺复苏设备

• 批准号: 2702495
• 负责人: Neil S. Rothman
• 金额: $ 35万
• 依托单位: CARDIOLOGIC SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 1999-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2702495
• 关键词: artificial respiration; biomedical device power system; biomedical equipment development; cardiopulmonary resuscitation; clinical biomedical equipment; clinical research; consumer product; electrocardiography; human subject; swine

Every year more than 300,000 people in the U.S. die of cardiac arrest. Currently, there is only a 15% success rate for manual CPR both in- hospital and out-of-hospital. The patented VEST-CPR system has the potential to significantly improve this outcome. Animal testing and preliminary human studies of the VEST-CPR system have shown a significant improvement in blood flow and return of spontaneous circulation. A hospital version of this system, developed by CardioLogic Systems (CSI), is currently in clinical trials in the U.S. and is approved for sale in Europe. Since at least half of all cardiac arrests occur out-of-hospital and the current version is too large for portable use, a portable system is needed to extend the benefits of Vest-CPR to these patients. Development of a portable VEST-CPR system presents engineering and scientific challenges. CSI has developed a conceptual design of such a device and has the expertise to turn this concept into a commercial product. The total VEST-CPR market is estimated to be nearly $3 billion. CSI proposes to demonstrate the feasibility of the portable VEST-CPR system and test a prototype in an animal model to prove its equivalence to the hospital version. PROPOSE COMMERCIAL APPLICATION: Cardiac arrest is one of the leading causes of death in the U.S and the world. Studies show that the best manual CPR has an average long-term survival rate of 15% both in-hospital and out-of-hospital. CSI expects long-term survival will double to at least 30% with the use of VEST-CPR, saving an estimated 45,000 additional lives per year in the U.S. alone. Marketing analysis estimates the combined U.S. and European markets for a portable VEST-CPR system to be at least $1.3 billion.

美国每年有30多万人死于心脏骤停。 目前，人工心肺复苏术的成功率只有15%， 医院和医院外。 专利的VEST-CPR系统具有 有可能显著改善这一结果。 动物试验和 VEST-CPR系统的初步人体研究显示， 改善血流和恢复自主循环。 一 该系统的医院版本，由CITALLOGIC系统公司（CSI）开发， 目前在美国进行临床试验，并已批准在美国销售。 欧洲 因为至少有一半的心脏骤停发生在医院外 而且当前版本对于便携式使用来说太大，便携式系统 需要将背心心肺复苏术的益处扩展到这些患者。 便携式VEST-CPR系统的开发提出了工程和 科学挑战。 CSI已经制定了这样一个概念设计， 设备，并拥有将这一概念转化为商业的专业知识 产品 VEST-CPR市场总额估计接近30亿美元。 CSI建议演示便携式VEST-CPR的可行性 系统并在动物模型中测试原型，以证明其与 医院版本 建议商业应用：心脏骤停是一种主要的 死亡原因在美国和世界。 研究表明， 人工心肺复苏术的平均长期存活率为15%， 和医院外。 CSI预计长期生存率将翻一番， 使用VEST-CPR至少节省30%，估计可额外节省45，000美元 仅在美国每年就有100万人死亡。 市场分析估计， 结合美国和欧洲市场的便携式VEST-CPR系统将在 至少13亿美元。